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Abstract
Visualizing the distributions of drugs and their metabolites is one of the key emerging application areas of
matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) within
pharmaceutical research. The success of a given MALDI-MSI experiment is ultimately determined by the
ionization efficiency of the compounds of interest, which in many cases are too low to enable detection at
relevant concentrations. In this work we have taken steps to address this challenge via the first application of
laser-postionisation coupled with MALDI (so-called MALDI-2) to the analysis and imaging of
pharmaceutical compounds. We demonstrate that MALDI-2 increased the signal intensities for 7 out of the 10
drug compounds analyzed by up to 2 orders of magnitude compared to conventional MALDI analysis. This
gain in sensitivity enabled the distributions of drug compounds in both human cartilage and dog liver tissue
to be visualized using MALDI-2, whereas little-to-no signal from tissue was obtained using conventional
MALDI. This work demonstrates the vast potential of MALDI-2-MSI in pharmaceutical research and drug
development and provides a valuable tool to broaden the application areas of MSI. Finally, in an effort to
understand the ionization mechanism, we provide the first evidence that the preferential formation of [M +
H]+ ions with MALDI-2 has no obvious correlation with the gas-phase proton affinity values of the analyte
molecules, suggesting, as with MALDI, the occurrence of complex and yet to be elucidated ionization
phenomena.
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ABSTRACT: Visualizing the distributions of drugs and their
metabolites is one of the key emerging application areas of
matrix-assisted laser desorption/ionization−mass spectrome-
try imaging (MALDI-MSI) within pharmaceutical research.
The success of a given MALDI-MSI experiment is ultimately
determined by the ionization efficiency of the compounds of
interest, which in many cases are too low to enable detection
at relevant concentrations. In this work we have taken steps to
address this challenge via the first application of laser-
postionisation coupled with MALDI (so-called MALDI-2) to
the analysis and imaging of pharmaceutical compounds. We
demonstrate that MALDI-2 increased the signal intensities for
7 out of the 10 drug compounds analyzed by up to 2 orders of
magnitude compared to conventional MALDI analysis. This
gain in sensitivity enabled the distributions of drug compounds in both human cartilage and dog liver tissue to be visualized
using MALDI-2, whereas little-to-no signal from tissue was obtained using conventional MALDI. This work demonstrates the
vast potential of MALDI-2-MSI in pharmaceutical research and drug development and provides a valuable tool to broaden the
application areas of MSI. Finally, in an effort to understand the ionization mechanism, we provide the first evidence that the
preferential formation of [M + H]+ ions with MALDI-2 has no obvious correlation with the gas-phase proton affinity values of
the analyte molecules, suggesting, as with MALDI, the occurrence of complex and yet to be elucidated ionization phenomena.
Determining the distributions of pharmaceutical com-pounds and their metabolites within tissues is an
important step in drug development. Mass spectrometry
imaging (MSI) is playing an increasing role in drug
development owing to its ability to simultaneously detect
and differentiate the spatial distributions of both drugs and
their metabolites while simultaneously imaging endogenous
biomolecules such as lipids, metabolites, and proteins.1 Various
desorption/ionization methods, including desorption electro-
spray ionization (DESI)2,3 and secondary ionization mass
spectrometry (SIMS),4−6 have been deployed for drug and
metabolite imaging in tissues and even individual cells.7−9 Of
these, matrix-assisted laser/desorption ionization (MALDI)
has been most widely utilized. Nowadays, imaging for
pharmaceutical compounds is one of the emerging applications
of MSI,10,11 which enables monitoring both drug metabolism
and pharmacokinetics (DMPK), even with absolute quantifi-
cation.12−14 MALDI-MSI typically offers the capability to
detect many molecular classes depending on the employed
sample preparation methods and spatial resolutions which can
be as low as 10 μm for commercial instruments15 and down to
∼1 μm for prototype systems.16,17 In addition to pharmaceut-
ical imaging, MALDI-MSI has been applied successfully in
different fields where both spatial and spectral information are
needed, such as pathology,18 clinical applications,19 biomarker
discovery,20 and forensics.21
MSI of pharmaceuticals (or any analyte) is not without
challenges. MALDI, like all ionization methods, suffers from a
low ionization efficiency for many analytes. Ionization
efficiencies (i.e., the ratio of MALDI-generated ions to
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desorbed neutrals) are estimated to be on the order of 1 ×
10−4 and lower.22−24 This imposes a significant sensitivity limit
as many molecules are not detected by mass spectrometry at
relevant concentrations. Furthermore, ionization efficiencies
can vary by orders of magnitude for different compounds and
it is often difficult to predict whether a given analyte will have a
higher ionization efficiency than another, thereby making the
success of a given MSI experiment hard to predict a priori.
This effect is augmented further in MSI studies where tissue-
dependent ion suppression effects can additionally inhibit
sensitivity heterogeneously within a sample.25,26 Given the fact
that ionization efficiency is a key factor in determining the limit
of detection, it is an important metric for quantitative
pharmaceutical-focused MSI studies.
Selective chemical derivatization of specific functional
groups of target analyte(s) is one strategy to improve
ionization efficiency. The most common approach is to
introduce a fixed-charge quaternary nitrogen group to the
analyte.27−29 However, derivatization also has drawbacks like
long reaction times (up to several hours for completion) and
potential delocalization masking the true distribution of target
compounds. Online derivatization methods, such as reactive
DESI, can help ameliorate these effects but typically has lower
spatial resolution than MALDI.30 An alternative method to
enhance MALDI ionization efficiencies is the use of
postionization strategies. These methods deploy a second
ionization event spatially and temporally separated from the
primary laser desorption event to increase the overall yield of
ions.31 Unlike derivatization, postionization does not require
additional sample preparation steps and can be performed
directly on samples prepared for conventional MALDI analysis.
For example, Lu et al. reported postionization using 118 nm
photons coupled with 532 nm direct laser desorption and
demonstrated significant sensitivity improvements for folic acid
detection in mouse tumor tissue.32 More recently, plasma
ionization coupled with atmospheric pressure MALDI also
revealed significant gains in sensitivity for a number of lipid
and drug species.33 Alternatively, Soltwisch et al. combined
laser postionization with MALDI using a UV OPO laser,
emitting photons capable of inducing two-photon ionization of
desorbed matrix molecules.34 To explain the enhancement of
ion yield, it is hypothesized that matrix radical cations formed
by photoionization interact with themselves and neutral
molecules in the still relatively dense MALDI plume. These
interactions form intermediate reactive species capable of
ionizing neutral molecules via protonation/deprotonation
processes (Supporting Information, Figure 1). This process
also shares many similarities with conventional MALDI in that
ionization is driven by initial ionization of the matrix and
subsequent ion/molecule reactions. This method, termed
MALDI-2, was shown to provide increased sensitivity, of up
to 2 orders of magnitude, for many lipid species.34,35 In this
work, we report the first application of MALDI-2 for the
enhanced detection and imaging of pharmaceutical com-
pounds. We demonstrate that the sensitivity for a variety of
tested compounds poorly ionized by MALDI was substantially
improved by MALDI-2 in the positive-ion mode. Combined,
this work represents a substantial leap in the analytical
capabilities of MALDI-MSI for studying drug metabolism in
tissues.
■ MATERIALS AND METHODS
Reagents and Solvents. 2,5-Dihydroxybenzoic acid
(DHB) and trifluoroacetic acid (TFA) were purchased from
Sigma-Aldrich (Zwijndrecht, The Netherlands). Ultrapure
water (LC-MS grade) and methanol (MeOH; HPLC grade)
were purchased from Fisher Scientific (Loughborough,
Leicestershire, U.K.). Ketoconazole, terfenadine, haloperidol,
doxorubicin, paclitaxel, kynurenine, triamcinolone acetonide
(TAA), caffeine, fluoxetine, and ibuprofen standards were
originally purchased from Fisher Scientific (Loughborough,
Leicestershire, U.K.). Dulbecco’s modified Eagle’s medium
(DMEM) and penicillin/streptomycin (P/S) were purchased
from Thermo Fisher Scientific (Waltham, MA, U.S.A.). Fetal
bovine serum (FBS) was purchased from HyClone (Eind-
hoven, The Netherlands) and ammonium acetate was
purchased from AMRESCO (Solon, OH, U.S.A.). Hematox-
ylin solution modified according to Gill and Entellan new was
purchased from Merck KGaA (Darmstadt, Germany).
Safranin-O and Fast Green were purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Eosine-Y, alcoholic,
was purchased from Avantor Performance Materials B.V.
(Deventer, The Netherlands), and coverslips were purchased
from Thermo Scientific (Waltham, Massachusetts, U.S.A.).
Tissue Collection. Cartilage. The cartilage was obtained
from an osteoarthritic patient undergoing total knee
arthroplasty and rinsed with PBS containing 1% P/S. Explants
from cartilage tissue (5 × 5 mm) were placed in a 24-well plate
and incubated with TAA (43.5 ng/μL) at a total volume of 500
μL for 48 h in a humidified incubator in an environment of 5%
CO2 and 37 °C. After the incubation, cartilage chips were
rinsed with ice-cold ammonium acetate buffer (150 mM, pH
7.3), snap-frozen in liquid nitrogen, and stored at −80 °C until
analysis.
Liver. Janssen R&D (Beerse, Belgium) provided canine liver
tissue dosed with drug compound A at 65 mg/kg. Liver was
resected, snap-frozen on aluminum foil floating on liquid
nitrogen, and subsequently stored at −80 °C until sectioning
and analysis. For confidentiality reasons, structural information
on the drug cannot be revealed and only nominal mass
information can be supplied.
All tissues were sectioned at 12 μm thickness and −20 °C
using a Leica cryostat (Leica Microsystems, Wetzlar,
Germany) and thaw mounted onto indium tin oxide (ITO)-
coated glass slides (4−8 Ω resistance, Delta Technologies,
U.S.A.) and stored at −80 °C until analysis.
MALDI Sample Preparation. Single Standard Analysis.
Ten compounds (ketoconazole, terfenadine, haloperidol,
doxorubicin, paclitaxel, kynurenine, triamcinolone acetonide,
caffeine, fluoxetine, and ibuprofen) were separately prepared
and mixed with DHB matrix solution (20 mg/mL, 70%
MeOH, + 0.2% TFA) obtaining a final drug concentration of
0.5 mg/mL. The full list of drugs can be found in the
Supporting Information, Table 1. The drug-matrix solution was
sprayed onto an ITO-coated glass slide using a TM-Sprayer
(HTX Technologies, U.S.A.) to obtain a homogeneous coating
of each drug/matrix mixture. The spraying parameters were as
follows: flow rate, 0.11 mL/min; velocity, 1200 mm/min;
temperature of the nozzle, 85 °C; track spacing, 2 mm; and
pressure, 10 psi. Diluted solutions were also prepared for
doxorubicin, paclitaxel (0.05 mg/mL), ketoconazole, terfena-
dine, and haloperidol (0.05 and 0.001 mg/mL) and sprayed
onto the glass slide using the same protocol.
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Triamcinolone Acetonide Sensitivity Evaluation. A
dilution series was prepared and mixed with DHB (20 mg/
mL prepared in 70% MeOH, 30% water, and 0.2% TFA) to
give final solution concentrations of 0.005, 0.01, 0.02, 0.05, 0.1,
0.2, 0.5, 1.0, 1.5, and 2.5 ng/μL. Each solution was sprayed
onto a separate glass slide. Ten layers of the matrix/TAA
solution were applied on the slide using the TM-Sprayer with
the same parameters described above.
Tissue Imaging. For tissue imaging experiments, 12 layers
of DHB (20 mg/mL prepared in 70% MeOH with 0.2% TFA)
were sprayed onto the tissue sections using the TM-sprayer:
flow rate, 0.11 mL/min; velocity, 1200 mm/min; temperature
of the nozzle, 75 °C; track spacing, 2 mm; and pressure, 10 psi.
Mass Spectrometry and Laser Postionization. An
Orbitrap Elite mass spectrometer (Thermo Fisher Scientific,
Bremen, Germany) coupled to an intermediate pressure
MALDI/ESI interface (Spectroglyph LLC, Kennewick, WA,
U.S.A.) was used for all experiments.36 Data were acquired in
the positive-ion mode at a mass resolution setting of 120000 or
240000 when mentioned (fwhm @ m/z 400) and an ion
injection time of 250 ms. Automatic gain control was disabled
in all experiments. Laser postionization (MALDI-2) was
performed as previously described.35 Unless reported other-
wise, all experiments were performed using a repetition rate of
100 Hz, a MALDI-2 wavelength in the 260−280 nm range, a
pulse energy of 500 μJ and a pulse delay time of 5 μs. Further
details are provided in the Supporting Information.
Data Acquisition. Drug Profiling. Each drug standard and
mixture was analyzed sequentially with MALDI-2 (100 Hz
repetition rate) and conventional MALDI (100 and 1000 Hz
repetition rate). Data were acquired by setting up a rectangular
scan area (50 μm step size) within which MALDI-2 data were
acquired for three rows after which the MALDI-2 laser was
disabled and MALDI data acquired. For data analysis, 50 scans
in each row were averaged to compare the signal intensity from
each experiment, while error bars were determined from the
standard deviation acquired from three consecutive rows. In
the case that analyte signals were unresolved from isotopes of
lower m/z fragments (e.g., [the M − H2 + H]+ ion of
terfenadine) isotope correction of ion intensities was
performed. The sensitivity evaluation only took in consid-
eration the concentrations presenting a signal-to-noise (S/N)
superior to 3 when averaging 50 scans. The S/N values were
provided by Thermo Xcalibur 3.0.63 software. To calculate the
concentration density per surface area, the values were
extracted from the HTX imaging software and converted in
ng/mm2.
Imaging Experiments. MSI data from human cartilage was
acquired across half the tissue using MALDI-2, after which the
MALDI-2 laser was disabled and MALDI-MSI data acquired.
For the dog liver sample, first 1 cm2 of tissue was acquired with
both MALDI and MALDI-2 to evaluate the postionization
benefits. Then, a consecutive full section was acquired at a
pixel size of 30 × 30 μm2. Data from cartilage was acquired at a
pixel size of 50 × 50 μm2. Tandem mass spectrometry (MS/
MS) was performed directly on tissue to identify triamcinolone
acetonide using resonance collision-induced dissociation in the
ion trap with a normalized collision energy of 30. An isolation
window of 1 m/z unit was employed.
Data Analysis. Spectral analysis and visualization were
performed using Thermo Xcalibur 3.0.63 and mMass 5.5.0.37
MSI data was reconstructed and visualized using in-house
developed software written in MATLAB (Matlab; Mathworks,
Natick, MA, U.S.A.; R2014a) as previously described.38 All
images are generated following total-ion-count normalization.
Tissue Staining. The intestine sections were stained with
hematoxylin and eosin (H&E). Cartilage tissue was stained
using safranin-O for 2 min and Fast Green. For more details,
please see Supporting Information.
Calculation of Gas-Phase Proton Affinities. Details on
gas-phase proton affinity calculations are provided in the
Supporting Information.
■ RESULTS AND DISCUSSION
Proof-of-Concept: Triamcinolone Acetonide. Triamci-
nolone acetonide (TAA), a corticosteroid used to treat pain
and inflammation, was chosen to evaluate the analytical merit
of MALDI-2. Previous studies required TAA derivatization
using Girard’s reagent T for detection of the drug from
cartilage tissues using MALDI-MSI.27 For analysis of the TAA
standard, the matrix-drug solution was sprayed onto an ITO-
coated slide. Using this standard, the alignment and timing of
the MALDI-2 laser were optimized to maximize the signal for
the [TAA + H]+ ion at m/z 435.2184. Regarding alignment,
practically, optimal MALDI-2 signal was obtained by bringing
the MALDI-2 laser as close as possible to the surface without
touching it (∼200−400 μm). Contact between the MALDI-2
laser and the sample surface can be observed by the presence
of matrix and/or drug signal when the desorption (MALDI)
laser is disabled. The highest TAA signal was achieved using a
delay time (the time between the MALDI and MALDI-2 laser
pulse) of 5−10 μs (Supporting Information, Figure 2A),
consistent with previous observations for small molecules
(Supporting Information, Figure 2B,C).34 The optimal delay
time is governed by the velocity of the desorbed analyte ions
and neutrals, which is largely determined by ion mobility-
related effects in this pressure regime (10 mbar). Figure 1
shows representative MALDI (bottom, blue trace) and
MALDI-2 spectra (top, red trace) acquired from the deposited
TAA standard. Using conventional MALDI, the [M + H]+ ion
of TAA observed at m/z 435.2184 was barely detectable while
Figure 1. Postionization-MALDI for TAA. MALDI (bottom, blue
trace) and MALDI-2 spectra (top, red trace) of triamcinolone
acetonide (TAA) standard (0.5 mg/mL). The [M + H]+ ion is
marked with a (■). Inset shows the m/z range where the [M + Na]+
ion of TAA is observed (indicated with a (◆)).
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the corresponding [M + Na]+ ion at m/z 457.2198 was
detected with a 42-fold higher intensity. Using MALDI-2, the
[M + H]+ ion was preferentially formed and exhibited 460- and
11-fold higher signals than the corresponding protonated and
sodiated molecules detected using conventional MALDI,
respectively. The formation of predominantly protonated
analyte (rather than alkali adducted species) using MALDI-2
is consistent with earlier reports on the use of MALDI-2 for
lipid imaging.34,35
Enhanced Detection of Multiple Drug Standards
Using MALDI-2. We next compared the signal intensities
generated from 10 different pharmaceutical compounds
(including TAA) analyzed using both MALDI and MALDI-
2. The full list of compounds is provided in Supporting
Information, Table 1. Prior to measurements, each drug was
individually mixed with DHB matrix solution to give a final
concentration of 0.5 mg/mL and sprayed onto separate slides.
The results from these experiments are provided in Figure 2,
while representative single-scan spectra and signal-to-noise (S/
N) values are provided in Supporting Information, Figure 3.
Figure 2A shows the comparative signal intensities generated
from the corresponding protonated molecules (with the
exception of ibuprofen, see below), produced using both
MALDI and MALDI-2.
Three compounds, ketoconazole (m/z 531.1556, [M +
H]+), terfenadine (m/z 472.3207, [M + H]+), and haloperidol
(m/z 376.1469, [M + H]+) produced the highest signal
intensities with conventional MALDI and the smallest
Figure 2. Sensitivity of MALDI-2 over MALDI for a panel of ten different compounds. (A) Absolute intensities for the [M + H]+ ([M]•+ for
ibuprofen) ions generated by MALDI (blue) and MALDI-2 (red) for 10 compounds at 0.5 mg/mL concentration. Error bars correspond to
standard deviation. Please note the logarithmic scale. (B) Representative MALDI (bottom, blue trace) and MALDI-2 (top, red trace) single scan
spectra for each compound shown in (A). Protonated species are marked with a (■) and radical cations indicated with a (●).
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fractional improvement with MALDI-2 improvements of ∼4-,
1.3-, and 2-fold, respectively. Terfenadine produced an
abundant fragment ion at m/z 470.3065 assigned to a [M −
H2 + H]
+ fragment (2.2 ppm mass error). This fragment was
only observed with MALDI-2 and was present at approx-
imately twice the intensity of the [M + H]+ ion (Supporting
Information, Figure 4). The observed MALDI-2-specific
fragmentation alludes to differences in the ionization
mechanisms of MALDI and MALDI-2.
A second regime of six compounds (doxorubicin, paclitaxel,
kynurenine, TAA, caffeine, and fluoxetine) exhibited greater
fractional enhancements using MALDI-2, with a signal
improvement for the [M + H]+ ions of at least 1 order of
magnitude observed for each compound. Kynurenine, TAA,
and caffeine showed, respectively, a 140-, 130-, and 380-fold
increase in signal for the [M + H]+ ion. As mentioned above,
MALDI-2-induced fragmentation was also apparent for
terfenadine. A fragment ion at m/z 286.1083 was observed
for paclitaxel and detected with comparable signal intensity as
the corresponding [M + H]+ ion generated using MALDI-2
(Supporting Information, Figure 5). This fragment is assigned
to the loss of the pentadecene ring-functionality forming a [M
+ H − C31H37O10]+ ion. Analogous fragment ions generated
from the deprotonated species have previously been reported
using MALDI and MS/MS in negative-ion mode.39,40 A ∼15-
fold gain was recorded for doxorubicin (m/z 544.1829; [M +
H]+).
While the above comparisons were focused on the relative
increase in protonated species, it is a common observation that
many compounds ionize more efficiently as [M + Na]+ ions.
Of these 10 compounds, four compounds produced more
abundant [M + Na]+ ions than [M + H]+ ions using
conventional MALDI (doxorubicin, paclitaxel, kynurenine, and
TAA). Thus, we compared the [M + Na]+ intensity of MALDI
with that of the [M + H]+ ion formed by MALDI-2. MALDI-2
still yielded overall higher intensities for these compounds, as
demonstrated in Supporting Information, Figure 6A.
We acknowledge the high concentration of drug standards
used to generate the data shown in Figure 2. For well-ionizable
compounds, this high concentration could potentially result in
signals that exceed the single-scan dynamic range of the
Orbitrap analyzer.41 We therefore analyzed five of the same
drug compounds following dilutions of between 10- and 500-
fold to evaluate the gain in signal for lower concentrations. As
shown in Figure 2, terfenadine, haloperidol, and ketoconazole
produced the highest MALDI and MALDI-2 signal intensities
and the lowest fractional improvement using MALDI-2. At a
500-fold dilution (0.001 mg/mL), the [M + H]+ signal
acquired using MALDI was twice higher than for MALDI-2 in
the case of terfenadine and 3× higher for haloperidol and near-
identical for ketoconazole (Supporting Information, Figure 7).
This shift in the preferred ionization mode can possibly be
explained by the dramatically higher matrix:analyte ratio of
these diluted solutions, which could alter the relative
efficiencies of the MALDI and MALDI-2 processes. Nonethe-
less, and in line with Figure 2, these three compounds still gave
the most similar ion intensities for MALDI and MALDI-2.
Doxorubicin and paclitaxel were analyzed at a 10-fold dilution
(0.05 mg/mL) and showed similar gains in signal intensity
observed for MALDI-2 as those provided in Figure 2
(Supporting Information, Figure 7). For these diluted
standards, we also compared the MALDI [M + Na]+ ion
formation with the [M + H]+ intensity from MALDI-2
showing that the protonated molecules obtained with MALDI-
2 presented higher signal than the MALDI-generated sodiated
ions (Supporting Information, Figure 7).
One compound, ibuprofen, was not detectable at all using
regular MALDI in the positive-ion mode. Interestingly
MALDI-2 analysis yielded higher signal for the corresponding
radical species (M+•) than for the closed-shell protonated
species. The latter observation is unsurprising given the acidic
nature of ibuprofen and the expectation that such species
would form deprotonated, negatively charged species with a far
greater efficiency. However, this observation also highlights a
second advantage of MALDI-2 with the ability to access
photoionization channels that are independent of typical
cationization/deprotonation ionization processes for analytes
that absorb the MALDI-2 laser light. It also highlights how
molecules can be liberated into the gas-phase by the primary
MALDI pulse but not ionized, such that they remain
undetected. In this case the formation of the [M]+• ion of
ibuprofen can be explained by a 2-photon resonance enhanced
multiphoton photoionization (REMPI) process. Ibuprofen
exhibits a peak UV-absorption at 263 nm, hence radical cation
formation can be attributed to absorption of the MALDI-2
laser light (λ = 260 nm)42 by ibuprofen and subsequent
absorption of a second photon ionizes the molecules. Radical
cations were also detected in the MALDI-2 analysis of
aromatic ketoconazole, doxorubicin, and caffeine (Figure 2B,
circle labels).
The ion generation rate of MALDI-2 is currently limited by
the relatively low repetition rate of the postionization laser
(100 Hz in our experimental setup). For typical MSI
applications the MALDI laser is operated at 1 kHz, which
enables total depletion of a sampling spot within the 250 ms
ion injection time. Therefore, we also compared the signal
intensity of MALDI-2 with the protonated and sodiated
molecules generated by conventional MALDI operating at 1
kHz. Overall, MALDI data generated with a laser repetition
rate of 1 kHz resulted in <1 order of magnitude gain compared
to 100 Hz (1.3-fold gain for ketoconazole to 8.1-fold gain for
ibuprofen; Supporting Information, Figure 6B). In this
analysis, MALDI-2 still provided higher signals for the
protonated species than MALDI, but for several species that
formed more abundant sodium adducts, MALDI generated
slightly higher intensities (e.g., ibuprofen and doxorubicin;
Supporting Information, Figure 6C).
MALDI-2 Sensitivity Evaluation. To test the sensitivity of
both conventional MALDI and MALDI-2, a range of TAA
concentrations were prepared and analyzed using both
methods by mixing TAA with a DHB matrix solution to give
final concentrations of 0.005−2.5 ng/μL sprayed on glass
slides (corresponding to 2.29 × 10−3−1.15 ng/mm2). Overall,
MALDI-2 produced higher signal for every concentration for
the protonated form of TAA, with up to a 13-fold higher signal
compared to the sodiated form. After averaging 50 consecutive
scans we were able to detect the protonated TAA down to 4.58
× 10−1 ng/mm2 with MALDI and 2.29 × 10−3 ng/mm2 with
MALDI-2, a 200-fold difference (Figure 3). For sodiated TAA,
MALDI-2 presented an overall higher signal. These results
indicate that MALDI-2 provides a higher analytical sensitivity
for TAA.
MALDI-2 Imaging of Pharmaceutical Compounds in
Tissue. Following the experiments on drug standards, we
evaluated the use of MALDI-2 for MSI applications,
specifically its ability to detect the distribution of two different
Analytical Chemistry Article
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pharmaceutical compounds in two different tissues. First, we
investigated the ability to detect TAA in human cartilage
tissues following their incubation for 48 h in a 24-well plate
containing a TAA solution. Previous work demonstrated that
MSI analysis of TAA in similar tissues was only possible after
chemical derivatization.43 Figure 4A shows that the [TAA +
H]+ ion from tissue was readily detected by MALDI-2, whereas
no [TAA + H]+ or [TAA + Na]+ signals were observed using
MALDI. Importantly, the acquired MALDI-2 signal intensity
was sufficient to study the distribution of TAA (Figure 4B,C)
and confirmed its identity using tandem mass spectrometry
(MS/MS; Supporting Information Figure 8).44 Consistent
with earlier reports using MALDI coupled with derivatization,
a relatively homogeneous distribution of the drug throughout
the tissue was observed.43
In addition, MALDI-2 was used to evaluate the liver
distribution of a drug under development, here referred to as
compound A. As an important candidate pharmaceutical
designed for the treatment of prostate cancer, it was canceled
due to toxicity issues observed in the form of fibrotic lesions in
the livers of treated dogs. Recently, compound A (the exact
identity and mass cannot be provided due to confidentiality
reasons) was visualized in canine liver tissue using desorption
electrospray ionization (DESI) imaging and multiple reaction
monitoring (MRM).45 Using both MALDI and MALDI-2, we
first screened a ∼ 1 cm2 of tissue obtained from a treated dog
which developed lesions. MALDI revealed a very low signal
intensity for the drug compound (for the expected [M + H]+
ion at m/z 502 and was not detected at all for [M + Na]+ ion)
after inspection of the averaged spectra across the analyzed
tissue regions. By contrast, MALDI-2 resulted in a 270-fold
improvement in signal of the [M + H]+ ion (Figure 4D).
Following this preliminary test, a full consecutive tissue section
was analyzed using MALDI-2, which enabled the ion
distribution to be studied throughout the tissue (Figure
Figure 3. Sensitivity comparison for TAA using both MALDI (blue:
squares, TAA [M + H]+; circles, TAA [M + Na]+) and MALDI-2
(red: squares, TAA [M + H]+; circles, TAA [M + Na]+).
Figure 4.MALDI-2-MSI. (A) MALDI (left, bottom) and MALDI-2 (left, top) MSI image of TAA distribution in cartilage. (B) The Safranin-O and
Fast green stained tissue section. (C) Average spectra obtained using MALDI-2 (top, red trace) and blue (bottom, blue trace) obtained from TAA-
dosed cartilage tissue. (D) MALDI-2 (top, red trace) and MALDI (bottom, blue trace) spectra obtained for dosed dog liver tissue but not by
MALDI (bottom). MALDI-2-MSI data for Compounds A, [M + H]+ (E), cholesterol, [M + H − H2O]+ (F), and vitamin E, [M]•+ (G). (H) H&E
staining of dog liver tissue obtain following MSI data acquisition. All MSI data are generated following total ion current normalization.
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.9b02495
Anal. Chem. 2019, 91, 10840−10848
10845
4E,H). The identity of the drug has been validated by MS/MS
and high mass resolution experiments (data not shown). In
addition to the drug distribution signal, numerous endogenous
lipid compounds were also observed, including a variety of
species not observed with MALDI (the full mass range
spectrum is provided in Supporting Information, Figure 9). For
example, the [M + H − H2O]+ ion of cholesterol observed at
m/z 369.3521 (0.2 ppm mass error) was observed throughout
the entire tissue, but with higher ion intensities in the lesions
(Figure 4F). The ability of MALDI-2 to access direct
photoionization channels was demonstrated as well as for the
radical cation of vitamin E at m/z 430.3812 (Figure 4G). This
ion signal was observed at far lower intensity in the lesions
compared to the surrounding tissue when compared to stained
tissue (Figure 4G,H).
Link between MALDI-2 Increased Signal and Proton
Affinity? The above results confirm previous reports that
MALDI-2 favors the formation of [M + H]+ ions,34,35
presumably through a proton transfer process initiated by
photoexcitation of matrix molecules. If it is assumed that the
source of the protons in these aforementioned experiments is
the same, then the gas-phase proton affinity of the analyte
species might be a key factor in dictating the efficiency of the
MALDI-2 process. To explore this, we calculated the gas-phase
proton affinities of each of the nine compounds for which
protonated signals were obtained and attempted to compare
this with the acquired MALDI and MALDI-2 data. For each
compound, multiple protonation sites are possible, and thus,
we considered the site with the largest affinity. The full list of
considered sites and calculated proton affinities is provided in
the Supporting Information Figures 10 and 11, as well as the
Supporting Information, Annex for more details.
No obvious correlation was apparent between the calculated
analyte proton affinities and either MALDI-2 signal intensity or
the fractional enhancement of MALDI-2 over MALDI,
suggesting the mechanism of protonation in MALDI-2 cannot
be explained by simple thermodynamically driven gas-phase
proton transfer (Supporting Information, Figure 12). This is
perhaps unsurprising, as the mechanisms of even conventional
MALDI remain poorly understood and an area of active
discussion in the literature.46−51 It is possible that MALDI-2 is
capable of protonating different functional groups than
conventional MALDI and that this contributes to the observed
signal enhancements. The coupling of MALDI-2 with ion
mobility to investigate the possible generation of different
protomer populations with MALDI and MALDI-2 could
provide an exciting avenue of future research to investigate
such effects.
There are several key differences between MALDI and
MALDI-2 that could potentially explain their ability to better
ionize different compounds. The higher energy photons used
for MALDI-2 are sufficient for direct two-photon ionization of
matrix molecules, which is believed to initiate the MALDI-2
ionization process. This is evidenced by the ≥2 order of
magnitude increase in signal intensity for the radical cation of
the matrix monomer observed with MALDI-2 (data not
shown). By contrast, MALDI typically uses photons in the
337−355 nm range, insufficient for direct two-photon
ionization of DHB52 and other common MALDI matrices.
In this case, photoionization of the matrix is thought to occur
either by energy-pooling processes or other complex
mechanisms involving close interactions between multiple
matrix and/or analyte molecules.46 Second, MALDI is
performed on a solid, crystalline sample whereas MALDI-2 is
performed on a desorbed, dense gas-phase matrix/analyte
containing plume. This likely presents a lower density reaction
plume than expected for MALDI. Moreover, in light of the
above results it is possible that proton transfer rates in the still
relatively dense MALDI plume ionized by MALDI-2 are not
dictated by gas-phase PA values. Moreover, there is no obvious
correlation between the presence of certain functional groups
and the signal enhancements observed using MALDI-2.
Combined with the likelihood of complex cluster chemistry,
it is clear there is much to unravel regarding the similarities and
differences in MALDI and MALDI-2 ionization mechanisms
and analyte-dependent ionization efficiencies. Thorough
evaluation of these parameters fall outside the scope of this
study.
■ CONCLUSIONS
The present study reports for the first time that the detection
and imaging of many pharmaceutically relevant compounds
can be significantly improved using MALDI-2. We demon-
strated that MALDI-2 can provide 1−2 orders of magnitude
improvement in sensitivity and signal intensity for a variety of
model compounds. Importantly, this sensitivity increase can
negate the need for time-consuming derivatization protocols
needed for certain compounds. As such MALDI-2 provides a
powerful a new tool enabling the MSI analysis of a variety of
compounds that are difficult to observe with MALDI. It can
offer benefits not only in the study of drug metabolism and
drug development, but also in studying the effects of
pharmaceuticals on endogenous metabolism by exploiting the
parallel increase in sensitivity provided by MALDI-2 for many
endogenous metabolites.34,35
As a first step toward rationalizing the observed differences
between MALDI and MALDI-2 we investigated the correlation
between analyte proton affinities and the signal gain realized by
MALDI-2 but no obvious correlation was found. A solid
understanding of the involved processes in MALDI-2
ionization, allowing prediction of optimal use of MALDI or
MALDI-2, remains so-far elusive. Nevertheless, the examples
clearly show the huge potential of using MALDI-2 for
improved sensitivity and further research will focus on better
understanding of underlying processes to better exploit its
abilities. Finally this work, in combination with other recent
studies31 highlights the vast potential of postionization
methods when coupled with modern MSI technologies in
overcoming the still low ionization efficiencies of most
compounds. Continued development and mechanistic under-
standing of such approaches has the potential of further
increasing efficiencies by several orders of magnitude.
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